European Journal of Clinical Pharmacology

, Volume 44, Issue 6, pp 579–582 | Cite as

On the bioavailability of 2-chloro-2-deoxyadenosine (CdA)

The influence of food and omeprazole
  • F. Albertioni
  • G. Juliusson
  • J. Liliemark


The pharmacokinetics of oral CdA (0.24 mg/kg) was studied in 4 patients (1 with hairy cell leukaemia and 3 with B-cell chronic lymphocytic leukaemia) to determine any effect of food and fasting with and without omeprazole.

Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting. The time to reach maximum concentration (tmax) was delayed about 0.8 h after food intake. Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C.V. 0.26 with and C.V. 0.27 without).

In conclusion, there was a small, though not statistically significant reduction in the bioavailability of CdA after food intake. Omeprazole did not significantly improve the bioavailability of CdA.

Key words

2-Chloro-2-deoxyadenosine (CdA) omeprazole food pharmacokinetics bioavailability 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kazimierczuk Z, Vilpo JA, Seela F (1993) Base-modified nucleosides related to 2-chloro-2-deoxyadenosine. Helv Chim Acta (in press)Google Scholar
  2. 2.
    Plunkett, W, Saunders PP (1991) Metabolism and action of purine nucleoside analogs. Pharmacol Ther 49: 239–268PubMedCrossRefGoogle Scholar
  3. 3.
    Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA (1985) Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75: 377–383PubMedCrossRefGoogle Scholar
  4. 4.
    Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med 322: 1117–1121PubMedCrossRefGoogle Scholar
  5. 5.
    Saven A, Carrera CJ, Beutler E, Carson E, Prio LD (1991) 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia Lymphoma 5 [Suppl]: 133–138Google Scholar
  6. 6.
    Juliusson G, Elmhorn-Rosenborg A, Liliemark J (1992) Complete response to 2-chloro-deoxyadenosine (CdA) in B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 327: 1056–1061PubMedCrossRefGoogle Scholar
  7. 7.
    Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD (1992) 2-chloro-deoxyadenosine treatment of lowgrade lymphomas. J Clin Oncol 10: 371–377PubMedGoogle Scholar
  8. 8.
    Santana VM, Mirro J Jr, Harwood FC, Kearns C, Schell MJ, Crom W, Blakley RL (1992) 2-chloro-deoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10: 363–370Google Scholar
  9. 9.
    Liliemark J, Juliusson G (1991) On the pharmacokinetics of 2-chloro-2-deoxyadenosine in human. Cancer Res 51: 5570–5572PubMedGoogle Scholar
  10. 10.
    Liliemark J, Albertioni F, Hassan M, Juliusson G (1992) On the bioavailability of oral and subcutaneous 2-chloro-2-deoxyadenosine in humans; Alternative routes af administration. J Clin Oncol, 10: 1514–1518PubMedGoogle Scholar
  11. 11.
    Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2-arabino-fluoro-2-deoxyadenosine. Proc Nat Acad Sci USA 89: 2970–2974PubMedCrossRefGoogle Scholar
  12. 12.
    Kazimierczuk Z, Cottam HB, Ravankar GR et al. (1984) Synthesis of 2-deoxytubercidin, 2-deoxyadenosine and related 2-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J Am Chem Soc 106: 6379–6382CrossRefGoogle Scholar
  13. 13.
    Beutler E (1992) Cladribine(2-Chlorodeoxyadenosine). Lancet 340: 952–956PubMedCrossRefGoogle Scholar
  14. 14.
    Liliemark J, Pettersson B, Juliusson G (1991) Determination of 2-chloro-2-deoxyadenosine in human plasma. Biomedical Chromatogr 5: 262–264CrossRefGoogle Scholar
  15. 15.
    Howeden CW, Forrest JAH, Ried JL (1984) Effect of single repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 24: 707–710Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • F. Albertioni
    • 1
  • G. Juliusson
    • 2
  • J. Liliemark
    • 1
    • 2
  1. 1.Department of Clinical PharmacologyKarolinska HospitalStockholmSweden
  2. 2.Division of Clinical Hematology and Oncology, Department of MedicineKarolinska Institute at Huddinge HospitalHuddingeSweden

Personalised recommendations